首页> 外文期刊>Cancers >A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients
【24h】

A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients

机译:口腔鳞状细胞癌患者血浆外泌体水平与预后相关性的初步临床研究

获取原文
       

摘要

Background: To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival. Methods: A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3–40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis. Results: Mean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 ( p = 0.091). On the other hand, CAV-1 positive plasmatic exosomes (EXO-CAV-1) increased after surgery from 507 ± 483.39 to 1120.25 ± 1151.17 ( p = 0.237). Patients with EXO-CD63 levels lower than the mean global value before the surgery had a survival of 36.04 months compared with the group with EXO-CD63 higher than the average who only survived 12.49 ± 1.67 months from the diagnosis, p = 0.225. When EXO-CAV-1 levels before surgery was lower than the average (813.94 ± 801.21) overall survival was 24.69 ± 22.23 months in contrast when it was higher that was only 11.64 months, p = 0.157. Patients with lower EXO-CD63 levels after surgery lived an average of 23.84 ± 23.9 months, while those with higher plasmatic levels of EXO-CD63 live 13.35 months, p = 0.808. When EXO-CAV-1 levels after surgery were lower, the average overall survival was 20.344 ± 15.40 months, in contrast when the EXO-CAV-1 levels were higher showing rather an estimate survival expectation of 1.64 months. Conclusions: Surgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients.
机译:背景:评价手术治疗前后OSCC患者血浆CD63和CAV1阳性外泌体水平之间的关系,并将其与总生存期相关联。方法:对10例无远处转移或局部骨浸润的OSCC和T4期患者进行了双盲先导研究。平均随访期为37.64个月(34.3–40.84)。我们在手术前和手术后7天分别获得2个血浆试管,每支1 mL。在进行基于免疫捕获的分析之前,先从血浆中分离出EV(细胞外囊泡),然后进行Western blot分析。结果:手术后CD63阳性血浆外泌体(EXO-CD63)的平均值从750.88±286.67降至541.71±244.93(p = 0.091)。另一方面,CAV-1阳性血浆外泌体(EXO-CAV-1)手术后从507±483.39增加到1120.25±1151.17(p = 0.237)。 EXO-CD63水平低于平均术前平均水平的患者的生存期为36.04个月,而EXO-CD63水平高于平均水平的患者在诊断后仅生存了12.49±1.67个月,p = 0.225。当手术前EXO-CAV-1水平低于平均水平(813.94±801.21)时,总生存期为24.69±22.23个月,而更高时仅为11.64个月,p = 0.157。手术后EXO-CD63水平较低的患者平均活23.84±23.9个月,而血浆EXO-CD63水平较高的患者则活13.35个月,p = 0.808。当手术后EXO-CAV-1水平较低时,平均总生存期为20.344±15.40个月,而当EXO-CAV-1水平较高时,则估计生存期为1.64个月。结论:手术治疗最早在切除术后1周引起了表达CD63的外泌体血浆水平的显着降低。第一个结果表明,肿瘤块是癌症患者中检测到的高水平循环外泌体的原因。同时,表达CAV-1的外泌体增加,可能是由于手术后立即发生的炎症反应。最后,统计分析表明,手术前后血浆外泌体的水平较低与OSCC患者的预期寿命更长相关。希望这种方法将在癌症患者的临床随访中被证明是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号